Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed diagnosis of 1 of the following hematologic
malignancies:

- Non-Hodgkin's lymphoma (NHL)

- Hodgkin's lymphoma

- Multiple myeloma

- Acute lymphoblastic leukemia

- Acute myeloid leukemia

- Chronic hematologic malignancy with a poor prognosis (e.g., failed 3 prior
standard therapies), including any of the following:

- Chronic lymphocytic leukemia

- Chronic myelogenous leukemia

- Indolent NHL

- Myeloproliferative disorders

- Refractory or relapsed disease, as defined by 1 of the following:

- Resistant to standard therapy for refractory or relapsed disease

- Progressed after standard therapy for advanced disease

- No effective treatment exists

- Measurable or evaluable disease

- No active CNS disease

- Previously treated leptomeningeal disease or brain metastases allowed provided
there is no evidence of remaining cancer by positron-emission tomography, MRI,
or spinal fluid cytology

PATIENT CHARACTERISTICS:

Age

- 18 and over

Performance status

- ECOG 0-2

Life expectancy

- At least 3 months

Hematopoietic

- Absolute neutrophil count ≥ 1,500/mm^3 (unless due to bone marrow involvement of
disease)

- Platelet count ≥ 75,000/mm^3 (unless due to bone marrow involvement of disease)

- Hemoglobin ≥ 8.0 g/dL (transfusion allowed)

- No coagulation disorders

Hepatic

- AST and ALT < 2.5 times upper limit of normal (ULN) (≤ 5 times ULN for patients with
liver metastasis)

- Bilirubin ≤ 1.5 times ULN

Renal

- Creatinine ≤ 1.5 times ULN

Cardiovascular

- No major cardiovascular disease

Pulmonary

- No major respiratory disease

Other

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective double-method contraception prior to study entry,
during study, and for at least 6 months after study participation

- No uncontrolled systemic infection

- No uncontrolled hypertriglyceridemia (i.e., triglyceride level > 500 mg/dL)

- No known HIV positivity

- No known allergy to egg products

- No known familial hyperlipidemia disorders

- No previously undiscovered hypertriglyceridemia

- No poorly controlled diabetes

PRIOR CONCURRENT THERAPY:

Biologic therapy

- Not specified

Chemotherapy

- More than 2 weeks since prior chemotherapy except hydroxyurea

- No concurrent hydroxyurea during study drug administration

- No other concurrent anticancer chemotherapy

Endocrine therapy

- No concurrent hormone-ablative agents

- No concurrent steroids

- No concurrent tamoxifen or any of its analogues

Radiotherapy

- No prior cranial radiotherapy

- More than 2 weeks since prior radiotherapy

Surgery

- More than 20 days since prior surgery except for biopsy

Other

- Recovered from all prior therapy

- More than 2 weeks since prior investigational agents

- No other concurrent investigational agents

- No other concurrent antineoplastic therapy

- No other concurrent antioxidants

- No concurrent herbal or other alternative therapies

- No concurrent vitamin supplements (e.g., vitamin A, ascorbic acid, or vitamin E)

- Standard dose multivitamin allowed

- No other concurrent medications that may act as modulators of intracellular ceramide
levels or ceramide cytotoxicity, sphingolipid transport, or p-glycoprotein or
multidrug resistance protein 1 (MRP1) drug/lipid transporters, including any of the
following:

- Cyclosporine or any of its analogues

- Verapamil

- Ketoconazole

- Chlorpromazine

- Mifepristone

- Indomethacin

- Sulfinpyrazone

- No concurrent medications that may cause pseudotumor cerebri, including any of the
following:

- Tetracycline

- Nalidixic acid

- Nitrofurantoin

- Phenytoin

- Sulfonamides

- Lithium

- Amiodarone

- No concurrent medication to control hypertriglyceridemia